Johnson & Johnson (NYSE:JNJ) Shares Acquired by Corepath Wealth Partners LLC

Corepath Wealth Partners LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 43.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,629 shares of the company’s stock after acquiring an additional 802 shares during the period. Johnson & Johnson makes up 0.3% of Corepath Wealth Partners LLC’s holdings, making the stock its 23rd biggest holding. Corepath Wealth Partners LLC’s holdings in Johnson & Johnson were worth $462,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Palisade Capital Management LLC NJ grew its holdings in shares of Johnson & Johnson by 0.3% in the first quarter. Palisade Capital Management LLC NJ now owns 93,141 shares of the company’s stock valued at $16,507,000 after purchasing an additional 250 shares in the last quarter. Lmcg Investments LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $12,462,000. Capital Wealth Planning LLC grew its holdings in shares of Johnson & Johnson by 14.0% in the first quarter. Capital Wealth Planning LLC now owns 916,575 shares of the company’s stock valued at $162,445,000 after purchasing an additional 112,890 shares in the last quarter. Tandem Investment Advisors Inc. grew its holdings in shares of Johnson & Johnson by 4.8% in the first quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after purchasing an additional 15,003 shares in the last quarter. Finally, Tcwp LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $946,000. 68.59% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE:JNJ opened at $177.01 on Thursday. The firm has a 50 day simple moving average of $168.35 and a 200-day simple moving average of $171.28. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a market capitalization of $462.79 billion, a PE ratio of 24.65, a P/E/G ratio of 3.49 and a beta of 0.57. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. During the same quarter in the prior year, the firm earned $2.60 EPS. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a $1.13 dividend. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 annualized dividend and a yield of 2.55%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Johnson & Johnson declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, September 14th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

A number of brokerages recently issued reports on JNJ. StockNews.com began coverage on shares of Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Credit Suisse Group began coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price target for the company. Barclays began coverage on shares of Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target for the company. Sanford C. Bernstein decreased their price target on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Finally, Atlantic Securities decreased their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Wednesday, October 19th. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $181.33.

Insider Activity at Johnson & Johnson

In related news, insider William Hait sold 15,000 shares of the company’s stock in a transaction on Monday, October 24th. The shares were sold at an average price of $171.55, for a total value of $2,573,250.00. Following the completion of the sale, the insider now owns 80,236 shares in the company, valued at approximately $13,764,485.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Hait sold 15,000 shares of the business’s stock in a transaction on Monday, October 24th. The shares were sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the completion of the transaction, the insider now directly owns 80,236 shares in the company, valued at $13,764,485.80. The disclosure for this sale can be found here. Insiders sold a total of 212,646 shares of company stock worth $36,791,022 in the last 90 days. 0.35% of the stock is owned by insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.